PBA
PLRX icon

Paradigm Biocapital Advisors’s Pliant Therapeutics PLRX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,197,050
Closed -$42.1M – 30
2024
Q4 		$42.1M Buy
3,197,050
+92,564
+3% +$1.26M 1.47% 17
2024
Q3 		$34.8M Buy
+3,104,486
New +$38.8M 1.18% 27

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Paradigm Biocapital Advisors's PLRX Position: Q1 2025 in Review

Paradigm Biocapital Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 3,197,050 shares — an estimated $42.1M sold.

Paradigm Biocapital Advisors first reported a position in PLRX in Q3 2024 and held it in 2 quarters. The position peaked at $42.1M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Paradigm Biocapital Advisors reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 3,197,050 Pliant Therapeutics shares in Q1 2025, an estimated $42.1M.
  • Paradigm Biocapital Advisors first reported a position in Pliant Therapeutics in Q3 2024 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Pliant Therapeutics position peaked at $42.1M in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2025, filed 15 May 2025.